OmniUltra™: An In Vivo Discovery Platform for Structured Peptides to Enable Radioligand Therapy and Other Applications
- OmniUltra is an in vivo discovery platform designed to identify compact, target-selective peptide ligands with potential advantages for radioligand therapy and other applications.
- Peptides are generated and optimized in vivo, using natural selection mechanisms to enrich for high-affinity target engagement, specificity, favorable size, and tunable pharmacokinetic clearance.
- OmniUltra harnesses immune-system biology which may enable identification of drug-like binders earlier in discovery compared to traditional approaches.